Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

TB prevention for kids: immediate treatment may stop infection before it starts

NCT ID NCT07086820

Prevention Sponsor: Pontificia Universidad Catolica de Chile Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether giving tuberculosis (TB) prevention drugs immediately to children and teens who live with someone with active TB can stop them from getting infected. About 647 participants aged 5 to 17 will be randomly assigned to receive either immediate treatment or standard care (treatment only if they test positive). The goal is to see if early treatment reduces new infections measured by a blood test after 12 weeks.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
isoniazid and rifapentine (weekly for 12 weeks)
What this could lead to
If successful, this approach could prevent many new TB infections in children and adolescents exposed at home, reducing the spread of TB.
What could go wrong
This is a relatively small trial (647 participants) in one country, so results may not apply everywhere. The window prophylaxis may not reduce infections more than standard care, and side effects from the drugs are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 647 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2025

Expected to finish

Nov 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

5 to 17 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Household contacts of patient (index case) with a new diagnosis of microbiologically confirmed pulmonary tuberculosis * Age ≥5 to \<18 years old Exclusion Criteria: * Suspected active tuberculosis in initial assessment (clinical or radiological) * Current pregnancy or breastfeeding * Immunocompromised * Allergy or contraindication to isoniazid or rifapentine * Chronic liver disease or alcohol use disorder * History of previous treatment for active or latent tuberculosis infection * Previous tuberculin skin test * Household contacts of a tuberculosis index patient with a known or suspected drug-resistant M. tuberculosis strain * Household contacts or a tuberculosis index patient currently living away from home for more than four weeks * Household contacts of a tuberculosis index patient who have already received more than 15 daily doses of antituberculous treatment

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Adolescent are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

tuberculosis latent tuberculosis infection prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Adolescent Children Household contacts Tuberculosis Tuberculosis infection Tuberculosis infection, latent

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    13 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Complejo Asistencial Dr. Sótero Del Río

    RECRUITING

    Puente Alto, Santiago Metropolitan, Chile

  • Hospital Alto Hospicio

    NOT_YET_RECRUITING

    Alto Hospicio, Tarapacá, Chile

  • Hospital CRS El Pino

    RECRUITING

    San Bernardo, Santiago Metropolitan, Chile

  • Hospital Claudio Vicuña

    NOT_YET_RECRUITING

    San Antonio, Valparaiso, Chile

  • Hospital Clínico Félix Bulnes

    RECRUITING

    Santiago, Santiago Metropolitan, Chile

  • Hospital Clínico San Borja Arriarán

    RECRUITING

    Santiago, Santiago Metropolitan, Chile

  • Hospital Dr. Carlos Cisterna

    RECRUITING

    Calama, Antofagasta, Chile

  • Hospital Dr. Gustavo Fricke

    NOT_YET_RECRUITING

    Viña del Mar, Valparaiso, Chile

  • Hospital Luis Calvo Mackenna

    NOT_YET_RECRUITING

    Providencia, Santiago Metropolitan, Chile

  • Hospital San Juan de Dios de La Serena

    NOT_YET_RECRUITING

    La Serena, Coquimbo Region, Chile

  • Hospital San Juan de Dios de Santiago

    NOT_YET_RECRUITING

    Santiago, Santiago Metropolitan, Chile

  • Hospital de Coquimbo

    NOT_YET_RECRUITING

    Coquimbo, Coquimbo Region, Chile

  • Hospital de Niños Roberto del Río

    NOT_YET_RECRUITING

    Independencia, Santiago Metropolitan, Chile

More trials for these conditions

Other studies related to the condition(s) this trial covers.